Interview Dr Adonis Saremi, Noom's Chief Medical Officer - GLP-1 Fact from Fiction

The new generation of GLP-1 medications like Ozempic and Wegovy are revolutionizing the treatment of obesity. Join Dr Adonis, CMO at Noom with Dayo Akinrinade Founder and GM at Noom Vibe, to explore the science behind the “Ozempic effect” and separate fact from fiction. - How GLP-1s actually work - Are GLP-1s truly a ‘miracle’ weight loss drug? - Debunking the myths about Ozempic - The potential impact of GPL-1s on longevity Bio Dr. Saremi is a dynamic and results-driven physician leader with dual board certification in Internal Medicine and Clinical Informatics, as well as board eligibility in Obesity Medicine. During the height of the public health emergency in 2020, he helped scale a start up telehealth group to over 150 physicians, serving more than 1000 patients daily. Dr. Saremi is currently the Interim Chief Medical Officer at Noom. He serves as a Judge for the Digital Health Hub awards held at the annual HLTH conference. He also serves on the Clinician Council of the American Telehealth Association (ATA). Noom Vibe is a free wellness community app empowering everyone, everywhere to live better, longer. The app makes it fun and rewarding to build healthy habits as part of a supportive community. Key features include an incentivized step and habit tracker, live conversations with coaches, and community connection. Noom Vibe is available now on the ⁠Apple App Store⁠ and ⁠Google Play⁠. To learn more about Noom Vibe, visit ⁠NoomVibe.com⁠.